Shuhei Nishiguchi

Author PubWeight™ 113.04‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009 14.16
2 Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005 2.44
3 Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002 1.79
4 Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004 1.78
5 Core protein of hepatitis C virus induces cardiomyopathy. Circ Res 2004 1.73
6 Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus. Am J Gastroenterol 2005 1.72
7 Alteration of gene expression in human hepatocellular carcinoma with integrated hepatitis B virus DNA. Clin Cancer Res 2005 1.64
8 Vitamin K2 (menatetrenone) for bone loss in patients with cirrhosis of the liver. Am J Gastroenterol 2002 1.42
9 Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006 1.40
10 Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum Mol Genet 2011 1.31
11 Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology 2006 1.31
12 Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 2014 1.23
13 Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol 2009 1.16
14 Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res 2007 1.13
15 Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol 2007 1.12
16 Detection of serum hepatitis B virus DNA by real-time quantitative polymerase chain reaction (TaqMan PCR) during lamivudine treatment: comparison with three other assays. Hepatol Res 2003 1.11
17 ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol Res 2010 1.09
18 Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update. Hepatol Res 2012 1.07
19 Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol 2014 0.98
20 p16 promoter hypermethylation in human hepatocellular carcinoma with or without hepatitis virus infection. Intervirology 2004 0.97
21 Interferon-gamma-mediated tissue factor expression contributes to T-cell-mediated hepatitis through induction of hypercoagulation in mice. Hepatology 2013 0.96
22 Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010 0.95
23 Problems in serum albumin measurement and clinical significance of albumin microheterogeneity in cirrhotics. Nutrition 2004 0.94
24 Serial changes in expression of functionally clustered genes in progression of liver fibrosis in hepatitis C patients. World J Gastroenterol 2008 0.94
25 Hepatitis B virus genotypes and response to antiviral therapy. Clin Lab 2006 0.94
26 Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: A case-control study. Hepatol Res 2006 0.94
27 L-carnitine inhibits hepatocarcinogenesis via protection of mitochondria. Int J Cancer 2005 0.93
28 Effect of oral supplementation with branched-chain amino acid granules on serum albumin level in the early stage of cirrhosis: a randomized pilot trial. Hepatol Res 2003 0.93
29 Disease associations and altered immune function in CD45 138G variant carriers. Hum Mol Genet 2004 0.92
30 Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences. J Med Virol 2007 0.92
31 A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 2007 0.91
32 Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis. World J Hepatol 2012 0.91
33 The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatol Res 2008 0.91
34 Oncostatin M gene therapy attenuates liver damage induced by dimethylnitrosamine in rats. Am J Pathol 2007 0.90
35 Hemodynamic analysis and treatment of an enlarging extrahepatic portal aneurysm: report of a case. Surg Today 2014 0.90
36 Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. J Gastroenterol 2013 0.90
37 New malignant grading system for hepatocellular carcinoma using the Sonazoid contrast agent for ultrasonography. J Gastroenterol 2013 0.89
38 Association of amino acid imbalance with the severity of liver fibrosis and esophageal varices. Ann Hepatol 2013 0.89
39 HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan. J Med Virol 2003 0.89
40 Ureterocolic fistula detected on bone scintigraphy. Indian J Gastroenterol 2004 0.88
41 Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan. J Med Virol 2005 0.88
42 Chemiluminescence enzyme immunoassay for monitoring hepatitis C virus core protein during interferon-alpha2b and ribavirin therapy in patients with genotype 1 and high viral loads. J Med Virol 2005 0.88
43 Comparison between mucinous cystic neoplasm and intraductal papillary mucinous neoplasm of the branch duct type of the pancreas with respect to expression of CD10 and cytokeratin 20. Pancreas 2009 0.88
44 Plummer-Vinson syndrome successfully treated by endoscopic dilatation. J Gastroenterol Hepatol 2007 0.88
45 Nutritional status and quality of life in current patients with liver cirrhosis as assessed in 2007-2011. Hepatol Res 2013 0.87
46 Involvement of hepatoma-derived growth factor in the growth inhibition of hepatocellular carcinoma cells by vitamin K(2). J Gastroenterol 2009 0.87
47 Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy: current status in Japan. Intern Med 2013 0.86
48 Crucial role of impaired Kupffer cell phagocytosis on the decreased Sonazoid-enhanced echogenicity in a liver of a nonalchoholic steatohepatitis rat model. Hepatol Res 2010 0.86
49 Nationwide survey in Japan regarding splenectomy/partial splenic embolization for interferon treatment targeting hepatitis C virus-related chronic liver disease in patients with low platelet count. Hepatol Res 2013 0.85
50 Differences of hepatocellular carcinoma patients with hepatitis B virus genotypes of Ba, Bj or C in Japan. Intervirology 2005 0.85
51 Primary squamous cell carcinoma of the liver: an uncommon finding in contrast-enhanced ultrasonography imaging. Case Rep Gastroenterol 2011 0.85
52 Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection. Hepatol Res 2011 0.85
53 Factors Associated With Protein-energy Malnutrition in Chronic Liver Disease: Analysis Using Indirect Calorimetry. Medicine (Baltimore) 2016 0.85
54 Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers. J Med Virol 2005 0.84
55 Multicentric occurrence of hepatocellular carcinoma in patients with a somatic mutation of mitochondorial DNA and hepatitis C virus. Hepatol Res 2003 0.84
56 Involvement of intracellular glutathione in zinc deficiency-induced activation of hepatic stellate cells. Chem Biol Interact 2003 0.84
57 Sequencing of human-viral DNA junctions in hepatocellular carcinoma from patients with HCV and occult HBV infection. J Med Virol 2003 0.84
58 Expression of connective tissue growth factor in the human liver with idiopathic portal hypertension. Mol Med 2007 0.84
59 Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B. Hepatol Res 2011 0.84
60 Correlation between clinical characteristics and mitochondrial D-loop DNA mutations in hepatocellular carcinoma. J Gastroenterol 2004 0.83
61 Hepatoma-derived growth factor is induced in liver regeneration. Hepatol Res 2009 0.83
62 Role of reactive oxygen species in zinc deficiency-induced hepatic stellate cell activation. Free Radic Biol Med 2005 0.83
63 Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res 2002 0.82
64 Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy. Hepatol Res 2014 0.82
65 LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. Hepatology 2012 0.82
66 Portal vein thrombosis following percutaneous ethanol injection therapy for hepatocellular carcinoma. Indian J Gastroenterol 2002 0.82
67 Two randomized controlled studies comparing the nutritional benefits of branched-chain amino acid (BCAA) granules and a BCAA-enriched nutrient mixture for patients with esophageal varices after endoscopic treatment. J Gastroenterol 2014 0.81
68 Usefulness of viral concentration measurement by transcription-mediated amplification and hybridization protection as a prognostic factor for recurrence after resection of hepatitis B virus-related hepatocellular carcinoma. Hepatol Res 2003 0.81
69 Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol 2008 0.81
70 Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. Hepatol Res 2006 0.81
71 Relationship between elevation of glycated albumin to glycated hemoglobin ratio in patients with a high bleeding risk of esophageal varices. Hepatogastroenterology 2012 0.81
72 Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. J Gastroenterol 2014 0.80
73 Development of a new in situ hybridization method for the detection of global bacterial DNA to provide early evidence of a bacterial infection in spontaneous bacterial peritonitis. J Hepatol 2011 0.80
74 Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. J Gastroenterol 2012 0.80
75 A new epitope of CYP2D6 recognized by liver kidney microsomal autoantibody from japanese patients with autoimmune hepatitis. Biol Pharm Bull 2005 0.80
76 Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol 2013 0.80
77 Effect of the presence of hepatitis B e antigen on prognosis after liver resection for hepatocellular carcinoma in patients with chronic hepatitis B. World J Surg 2002 0.80
78 Thiopurine S-methyltransferase gene polymorphism in Japanese patients with autoimmune liver diseases. Liver Int 2007 0.80
79 LKM-1 sera from autoimmune hepatitis patients that recognize ERp57, carboxylesterase 1 and CYP2D6. Drug Metab Pharmacokinet 2010 0.79
80 Gastric emptying in patients with chronic liver diseases. Ann Nucl Med 2002 0.79
81 Lamivudine therapy for hepatitis B virus reactivation in a patient receiving intra-arterial chemotherapy for advanced hepatocellular carcinoma. Hepatol Res 2003 0.79
82 Vitamin K2 inhibits the proliferation of HepG2 cells by up-regulating the transcription of p21 gene. Hepatol Res 2007 0.79
83 Lack of mitochondrial DNA enhances growth of hepatocellular carcinoma in vitro and in vivo. Hepatol Res 2006 0.79
84 Prevalence of hepatitis C virus infection among patients with hypertrophic cardiomyopathy. Heart Vessels 2003 0.79
85 Cyclical etidronate for treatment of osteopenia in patients with cirrhosis of the liver. Hepatol Res 2002 0.79
86 Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. Hepatol Res 2006 0.79
87 Alcohol abuse as an etiologic factor for hepatocellular carcinoma in Japan. Hepatol Res 2005 0.78
88 Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma. Hepatol Int 2010 0.78
89 Investigation of interferon-α response by a single amino acid substitution of nonstructural protein 5A in hepatitis C virus-infected patients. J Interferon Cytokine Res 2011 0.78
90 Comparison of the effect of BCAA granules on between decompensated and compensated cirrhosis. Hepatogastroenterology 2010 0.78
91 Clinicopathologic features and outcome after liver resection for hepatocellular carcinoma in patients with concurrent versus previous chronic hepatitis B. Surg Today 2005 0.78
92 Differences in molecular alterations of hepatocellular carcinoma between patients with a sustained virological response and those with hepatitis C virus infection. Liver Int 2008 0.78
93 Natural history of major complications in hepatitis C virus-related cirrhosis evaluated by per-rectal portal scintigraphy. World J Gastroenterol 2005 0.78
94 Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor. Cancer Sci 2006 0.78
95 Survey of non-B, non-C liver cirrhosis in Japan. Hepatol Res 2013 0.78
96 Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma. Oncol Rep 2013 0.78
97 Effects of exercise and grape juice ingestion in combination on plasma concentrations of purine bases and uridine. Clin Chim Acta 2007 0.77
98 Mode of HCV infection examined by polymorphism of hypervariable region-1 in cases of acute hepatitis C after accidental exposure to blood-borne pathogens. J Med Virol 2005 0.77
99 Elevation of the AST to ALT ratio in association with the severity of esophageal varices in patients with HCV-related compensated liver cirrhosis. Hepatogastroenterology 2013 0.77
100 Lamivudine and IFN-beta sequential therapy in HBe antigen-positive patients with chronic hepatitis B virus genotype C infection. J Interferon Cytokine Res 2007 0.77
101 Serum hyaluronic acid predicts protein-energy malnutrition in chronic hepatitis C. Medicine (Baltimore) 2016 0.77
102 Guidelines on nutritional management in Japanese patients with liver cirrhosis from the perspective of preventing hepatocellular carcinoma. Hepatol Res 2012 0.77
103 Relationship Between Hepatic Steatosis and the Elevation of Aminotransferases in HBV-Infected Patients With HBe-Antigen Negativity and a Low Viral Load. Medicine (Baltimore) 2016 0.77
104 Does alcohol increase the risk of hepatocellular carcinoma among patients with hepatitis C virus infection? Hepatol Res 2006 0.77
105 Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts. Hepatol Res 2008 0.77
106 Hepatitis C virus relapse was suppressed by long-term self-injection of low-dose interferon in patients with chronic hepatitis C after pegylated interferon plus ribavirin treatment. Hepatol Res 2013 0.76
107 A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan. Hepatol Int 2009 0.76
108 Mechanisms of the protective effect of L-alanine to D-galactosamine-induced hepatocellular injury: comparative studies of L-alanine and pyruvate. Biochem Biophys Res Commun 2002 0.76
109 Potential role of vitamin K(2) as a chemopreventive agent against hepatocellular carcinoma. Hepatol Res 2007 0.76
110 Partial blockage of hepatocyte maturation in hepatoma-derived growth factor transgenic mice. World J Hepatol 2009 0.76
111 Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography. Hepatol Res 2012 0.76
112 Dynamics of hepatitis C virus monitored by real-time quantitative polymerase chain reaction during first 2 weeks of IFN-beta treatment are predictive of long-term therapeutic response. J Interferon Cytokine Res 2002 0.76
113 Does a late evening meal reduce the risk of hepatocellular carcinoma among patients with chronic hepatitis C? Hepatol Res 2008 0.75
114 B-Cell Activating Factor Belonging to the Tumor Necrosis Factor Family and Interferon-γ-Inducible Protein-10 in Autoimmune Hepatitis. Medicine (Baltimore) 2016 0.75
115 A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation. Medicine (Baltimore) 2016 0.75
116 Natural course of changes in hepatic functional reserve in patients with chronic liver diseases evaluated by scintigraphy with GSA. Hepatol Res 2003 0.75
117 A proposed predictive model for advanced fibrosis in patients with chronic hepatitis B and its validation. Medicine (Baltimore) 2016 0.75
118 Effect of psoas muscle mass after endoscopic therapy for patients with esophageal varices. Medicine (Baltimore) 2017 0.75
119 Prognostic significance of nonprotein respiratory quotient in patients with liver cirrhosis. Medicine (Baltimore) 2017 0.75
120 SEN viruses and treatment response in chronic hepatitis C virus. Lancet 2002 0.75
121 Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C. Hum Genet 2014 0.75
122 Changes in skeletal muscle mass after endoscopic treatment in patients with esophageal varices. Medicine (Baltimore) 2017 0.75
123 Time Course of Change in Glutathione S-Transferase Positive Foci and Ornithine Decarboxylase Activity after Cessation of Long-term Alcohol Administration in Rats. Asian Pac J Cancer Prev 2001 0.75
124 [Sequential therapy with a nucleos(t)ide analogue and interferon in patients with chronic hepatitis B: efficacy and limitations]. Nihon Shokakibyo Gakkai Zasshi 2011 0.75
125 Timing of interferon therapy and sources of infection in patients with acute hepatitis C. Hepatol Res 2005 0.75
126 Adefovir dipivoxil to prevent exacerbation of lamivudine-resistant hepatitis B infection during chemotherapy for non-Hodgkin's lymphoma. Am J Gastroenterol 2004 0.75
127 An autopsy case of POEMS syndrome with a high level of IL-6 and VEGF in the serum and ascitic fluid. Intern Med 2002 0.75
128 Regional hepatic regeneration after liver resection correlates well with preceding changes in the regional portal circulation in humans. Dig Dis Sci 2013 0.75
129 Two cases of intrahepatic cholangiocarcinoma detected after interferon therapy for chronic hepatitis C. Hepatogastroenterology 2005 0.75
130 Gastric ulcer detected incidentally by renal scintigraphy. Indian J Gastroenterol 2004 0.75
131 Sarcopenia and Sarcopenic Obesity Are Prognostic Factors for Overall Survival in Patients with Cirrhosis. Intern Med 2016 0.75
132 Does colitis associated with primary sclerosing cholangitis represent an actual subset of ulcerative colitis? Hepatogastroenterology 2003 0.75
133 [Present status of community-based HCV screening in Osaka City and evaluation of the utility of follow-up programs on hepatitis]. Nihon Koshu Eisei Zasshi 2008 0.75
134 [PEG-IFN/IFN monotherapy]. Nihon Rinsho 2015 0.75
135 Changes in serum levels of hepatitis C virus genotype 1b monitored by real-time quantitative polymerase chain reaction as a predictor of long term response to interferon-alpha treatment. Am J Gastroenterol 2002 0.75
136 Polyamine metabolism and recurrence after resection for hepatocellular carcinoma. Hepatogastroenterology 2004 0.75
137 Hepatocellular carcinoma fed by an aberrant posterior right hepatic artery. Hepatogastroenterology 2003 0.75
138 A new era of the HCV treatment with oral agents. Nihon Shokakibyo Gakkai Zasshi 2016 0.75
139 Vitamin K2 downregulates the expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma cells. Hepatol Res 2009 0.75
140 [Non-invasive assessment of liver fibrosis: Ultrasound elastography and MR elastography]. Nihon Rinsho 2015 0.75
141 Ultrasonographic diagnosis of degree of chronic type C liver disease. Hepatogastroenterology 2005 0.75
142 [A case of hepatocellular carcinoma with autoimmune hepatitis showing marked reduction of tumors by oral administration of UFT-E]. Gan To Kagaku Ryoho 2010 0.75
143 Optimal duration of additional therapy after biochemical and virological responses to lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomized trial. Hepatol Res 2008 0.75
144 [Diagnosis of liver fibrosis in patients with chronic hepatitis using serum enhanced liver fibrosis (ELF)]. Nihon Rinsho 2015 0.75
145 [Epidemiology of hepatitis C virus and hepatocellular carcinoma in Japan]. Nihon Rinsho 2004 0.75
146 Retreatment with peginterferon α-2a + ribavirin in patients who failed previous peginterferon α-2b + ribavirin combination therapy. Dig Dis 2012 0.75
147 [Prevalence and clinical course in HBV and HCV dual chronic infection]. Nihon Rinsho 2004 0.75
148 [Mechanism and clinical application of carcinogenesis control by IFN]. Nihon Rinsho 2006 0.75
149 Effects of marker for hepatic fibrosis and viral status on recurrence after resection of hepatitis B virus-related hepatocellular carcinoma. Hepatogastroenterology 2003 0.75
150 Cessation of Long-term Alcohol Administration and Two-day Cycling of Exposure Respectively Promote and Inhibit Hepatocarcinogenesis in Rats. Asian Pac J Cancer Prev 2000 0.75
151 Successful pediatric living donor liver transplantation from carrier to carrier of hereditary butyrylcholinesterase variant. Pediatr Transplant 2007 0.75
152 [Splenectomy before antiviral therapy for patients with chronic hepatitis C with thrombocytopenia]. Nihon Rinsho 2011 0.75
153 Previous or occult hepatitis B virus infection in hepatitis B surface antigen-negative and anti-hepatitis C-negative patients with hepatocellular carcinoma. Surg Today 2004 0.75
154 Abdominal ultrasonography as a new modality for the diagnosis of gastroesophageal reflux disease. J Gastroenterol Hepatol 2010 0.75